丙酮酸羧化酶通过激活AKT通路促进子宫内膜异位症进展
本研究探讨丙酮酸羧化酶是否驱动子宫内膜异位症进展及其机制。临床标本免疫组化显示,患者在位及异位内膜中丙酮酸羧化酶表达显著上调(P=0.022和P<0.001)。体外与小鼠模型证实其促进疾病进展,机制涉及AKT通路调控糖酵解酶表达,抑制剂ZY-444和没食子酸辛酯可减轻进展。
要点
- 子宫内膜异位症患者在位及异位内膜中丙酮酸羧化酶表达显著上调。
- 丙酮酸羧化酶通过激活AKT通路调控糖酵解酶并促进异位症进展。
- 丙酮酸羧化酶抑制剂ZY-444和没食子酸辛酯可减轻小鼠异位症进展。
核心结论
- 丙酮酸羧化酶在子宫内膜异位症患者在位及异位内膜中显著上调,通过激活AKT通路调控糖酵解酶表达并促进疾病进展。
研究设计与样本
- 临床子宫内膜标本行免疫组化检测丙酮酸羧化酶表达。
- 永生化人子宫内膜异位间质细胞(ihESC)中敲低或过表达丙酮酸羧化酶后,用EdU、集落形成和Transwell实验评估增殖与迁移。
- 采用准靶向代谢组学、RNA测序和蛋白质印迹探索下游分子变化。
- 应用同种异体小鼠子宫内膜异位模型进行体内功能验证。
主要发现
- 与对照相比,患者在位内膜(P=0.022)和异位内膜(P<0.001)中丙酮酸羧化酶表达显著上调。
- 体外和体内实验显示丙酮酸羧化酶促进子宫内膜异位症进展。
- 准靶向代谢组学显示敲低丙酮酸羧化酶降低ihESC中糖酵解代谢物丰度。
- RNA测序和蛋白质印迹鉴定丙酮酸羧化酶增强磷脂酰肌醇3-激酶-AKT通路活性。
- 使用AKT激动剂SC79和抑制剂AZD5363证明丙酮酸羧化酶通过AKT通路调节糖酵解酶表达和疾病进展。
临床怎么用
- 丙酮酸羧化酶及其下游AKT通路可能作为子宫内膜异位症代谢重编程的干预靶点。
- 丙酮酸羧化酶抑制剂ZY-444和没食子酸辛酯在模型中显示减轻疾病进展的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RESEARCH QUESTION: Does pyruvate carboxylase drive the progression of endometriosis, and, if so, what is the underlying mechanism? DESIGN: The expression of pyruvate carboxylase in clinical endometrial specimens was examined via immunohistochemistry. After knockdown or overexpression of pyruvate carboxylase in immortalized human endometriotic stromal cells (ihESC), cell proliferation and migration were assessed using 5-ethynyl-2'-deoxyuridine (EdU), colony formation and Transwell assays. Quasi-targeted metabolomics, RNA sequencing and western blotting were adopted to explore downstream molecular changes, and an allogeneic mouse endometriotic model was applied for in-vivo functional verification. RESULTS: Expression of pyruvate carboxylase was up-regulated significantly in eutopic and ectopic endometrial tissues of patients with endometriosis compared with controls (P = 0.022 and P < 0.001, respectively). In-vitro and in-vivo experiments showed that pyruvate carboxylase promoted the progression of endometriosis. In addition, quasi-targeted metabolomics showed that knockdown of pyruvate carboxylase decreased the abundance of glycolytic metabolites in ihESC. Furthermore, RNA sequencing and western blotting identified that pyruvate carboxylase enhanced activity of the phosphoinositide-3-kinase-AKT pathway. Using AKT agonist (SC79) and inhibitor (AZD5363), pyruvate carboxylase was shown to modulate the expression of glycolytic enzymes and the progression of endometriosis through the AKT pathway. Finally, pyruvate carboxylase inhibitors ZY-444 and octyl gallate attenuated the progression of endometriosis. CONCLUSIONS: Pyruvate carboxylase is up-regulated significantly in eutopic and ectopic endometrial tissues from patients with endometriosis, and modulates the expression of glycolytic enzymes as well as the progression of endometriosis via activation of the AKT pathway. These findings provide mechanistic insight into the metabolic reprogramming underlying the pathogenesis of endometriosis.
引用
- Wu Y, Ye X, Jin O, et al. Pyruvate carboxylase promotes progression of endometriosis by activating the AKT pathway. Reprod Biomed Online. 2026. PMID: 42641507. doi:10.1016/j.rbmo.2026.105889
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。